[Compass Pathways; synthetic-psilocybin patenting British bio-tech company]… a securities purchase agreement with a select group of healthcare specialist investors for the private placement of… American Depositary Shares… Morgan Stanley and TD Cowen are acting as the placement agents for the private placement. The securities to be sold in the private placement, including the ADSs underlying…
Christian Angermayer (billionaire) owns an extensive art collection that includes ancient artifacts highlighting the role that psychedelics have played in human history… that is, the inventors’ definition controls, “even if it is contrary to the conventional meaning of the term” according to Christopher G. Paulraj, Tina E. Hulse, & Sheridan K. Snedden… the U.S. Patent…
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC [partnered with MAPS and Rick Doblin] and [Peter Theil & Christian Angermayer backed] COMPASS Pathways… On March 3 [2023], the AMA published its Panel Actions summary which included…
London-based Compass Pathways PLC, which has adopted the conventional biotech strategy of modifying naturally existing psilocybin into a patentable drug and taking it through clinical trials. The firm, founded in 2020, boasted a stock market value of $2 billion in November 2021, but its shares since have slumped 80 percent. Small Pharma, a small Canadian…
The analog of psilocybin that Gilgamesh is developing has been designed to eliminate the hallucinogenic experiences that are often set off by so-called magic mushrooms. Researchers working with the company [including team members from ATAI, Pfizer, Johnson & Johnson, etc], administer test drugs [new chemical entities] to mice and then capture their reactions using video…
Compass… phase 2B data, which has yet to be formally published in a peer-reviewed journal… with five patients (6.3%) in the 25-mg group and six patients (8%) in the 10-mg group experiencing serious adverse events during the follow-up period…. These adverse events included suicidal ideation and suicidal behavior. The first Phase 3 trial has been…
Robin Feldman, an expert on pharmaceutical intellectual property at the University of California Hastings College of Law… …said the conflict over psychedelics reflects the larger problems of a patent system that saddles Americans with some of the highest prescription drug prices in the world. “It’s not pretty when you look under the hood,” she said.…
It won’t be long before politicians trip together to resolve their differences… billionaire German investor Christian Angermayer, says. Right now, though, the charm offensive isn’t working so well. An exchange-traded fund tracking psychedelic stocks has lost two-thirds of its value since peaking last year. While some of these companies haven’t suffered as much… the comedown…
Compass sinks after depression therapy results… the net loss for the year [2021] was $71.7 million… …Compass doesn’t have any meaningful revenue… continues to explore… indications and therapeutic approaches… there were 12 people in the [synthetic psilocybin polymorph] study… who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. Original Article (Green Market…
Compass will now have three months to respond to each filing. Then, the Patent Trial and Appeal Board, a collection of administrative judges… will make a decision as to whether the petitioner demonstrates that at least one of the challenged claims is “more likely than not” unpatentable—and whether the case should proceed to a trial.…
Recent Comments